 |
|
|
Home > Research & Development > Central
Nervous System
| Drugs in Development |
|
| Definition |
Chronic neuropathic pain is a type of pain that results from nerve damage and is characterized by an abnormal hypersensitivity to innocuous, as well as noxious stimuli. |
| Effects |
| This type of pain is extremely difficult to manage, fails to respond to standard analgesic interventions, and often worsens over time. |
| Facts |
| The neuropathic pain market has become one of the most sought-after in the pharmaceutical industry. The global neuropathic pain market is forecast to grow to $5.5 billion by 2015 (Datamonitor, 2006). |
| DARA's Approach |
| Current approved therapeutic agents often have intolerable side effects and limited efficacy. Thus, there is an urgent need to develop safe and effective drugs to treat neuropathic pain. |
| Drugs in Development |
|
| Definition |
A chronic and progressive condition, Parkinson’s disease is characterized by four main symptoms:
- Tremors or trembling in the hands, arms, legs, jaw and face;
- Rigidity or stiffness of the limbs and trunk;
- Bradykinesia or slowness of movement; and
- Postural instability or impaired balance and coordination.
|
| Effects |
As the disease progresses, patients may have difficulty walking, talking or completing simple tasks. Other effects include skin changes, sleep problems, dementia and emotional changes such as depression. |
| Facts |
| With more than 50,000 new cases diagnosed annually in the United States, at least 500,000 people are believed to suffer from the disease. |
| DARA's Approach |
| DARA has invested in the research of devices that help treat and control the symptoms of this debilitating disease. |
|
|
Central
Nervous System